

STRONG GROWTH DRIVEN BY ATTENDO ACQUISITION AND GOOD UNDERLYING GROWTH

CEO Yrjö Närhinen CFO IIkka Laurila



<u>Terveystalo</u>

12.33

Terveystalo oma Terveys 24/7

Näytä kaikk

Nayta kalkki

EDUT

UUSI ALKU OM

Q2 HIGHLIGHTS

terveystalo.com

#tervevstalo

in f 🕑 🖸

E

Strong development in all customer groups

Attendo Health care integration is proceeding as planned

Strong revenue growth in preventive and well-being services continued, slight upward trend in illness-related appointments

KSESTA9


crusivu.

Tapahtumat Terveystiedot Artikkelit

Remote appointments at an all time high, new solutions improve availability of services

Remote services improve access to care

- New Terveystalo Remote appointment app launched
- Chat-appointments at all time high in the summer
- Pre-bookable remote appointment as a new service improves access to care and helps in managing supply and demand, one solution to doctor shortage




Q2: Attendo deal and solid organic growth increased revenue significantly

Strong growth in all customer groups

- Corporate: Preventive and wellbeing services, particularly wellbeing and digital services, are on the rise, slight upward trend in illness-related appointments.
- In addition to acquisitions, private customer revenue was boosted by strong demand for oral health, well-being services and digital services.
- Public customer revenue more than tripled; In addition to the acquisition of Attendo Health Services, occupational health services grew significantly, steady growth in other service sales and outsourcing.
- Q2 had one business day less, which had a negative effect on revenue.

Q2 Revenue by payor group, %








H1 Revenue by payor group, %

H1 Revenue by payor group, M€






Q2: Strong profitability

 Relative profitability was negatively impacted by change in sales mix, lower margin of Attendo business, negative working day impact and positive one offs in the comparison period

Terveystalo

- Adjusted EBITA EUR 25.9 million (20.2)
- Adjusted EBITA % 10% of revenue (10.7%)
- Profit for the period* EUR 10.4 million (15.4)

*Figures for the reference period were impacted by the non-recurring capital gains totaling EUR 7.8 million



Terveystalo

Market review

- There were no material changes in the healthcare market during the reporting period.
- Strong demand for Terveystalo's services among the corporate and private customer groups continued.
- It is estimated that the Government's new health care policies will reduce the number of full outsourcings of health care services in the public sector but, on the other hand, the demand for various types of partial outsourcings and health care staffing services is expected to grow. The use of service voucher is also expected to increase.
- However, the impact is expected to be low in 2019 because of the long duration of the procurement processes.

Market outlook

- Market environment remains positive despite weakened consumer confidence.
- With the healthcare and social welfare reform still being delayed, demand in the public sector is expected to grow.
- Corporate customers keep up a steady demand, and the relative share of preventive services is increasing.
- Private customer demand also remains at a steady level but new capacity that entered the market at beginning of 2018 still has a negative impact on Terveystalo's revenue growth. This capacity growth has reached its peak, however.
- These views are based on the expected market development within the next six months, compared to the last six months.






FINANCIAL PERFORMANCE

CFO IIkka Laurila



Strong profitability despite the impact of Attendo

Revenue, Adjusted EBITDA*, % Before IFRS 16 impact (comparable)




Adjusted EBITA*, M€and % Before IFRS 16 impact (comparable)

* Vaihtoehtoinen tunnusluku

Terveystalo

Operating leverage still applies, the scale has changed post Attendo




*Adjustments are material items outside the ordinary course of business associated with acquisition-related expenses, restructuring-related expenses, gain on sale of assets, strategic projects including the IPO and other items affecting comparability.

ا

Terveystalo

The impact of the Attendo deal and the adoption of IFRS 16 is reflected in the balance sheet




Total assets of the Group amounted to EUR 1,361.3 million (EUR 933.6 million). The growth was mainly attributable to the allocation of the purchase price to intangible assets in connection with the Attendo acquisition, the goodwill generated by the acquisition, and the adoption of IFRS 16.

- Equity attributable to owners of the parent company totaled EUR 514.3 (492.9) million. The growth was mainly due to improved profitability.
- Gearing at the end of the review period was 111.4 (44.2) percent, and net interest-bearing debt amounted to EUR 572.9 (218.0) million. The effect of IFRS 16 on lease-related interestbearing debt was EUR 181.4 million.

Terveystalo

The financing of the Attendo deal and the <u>Terveystalo</u> adoption of IFRS 16 increased net debt




The share of intangible investments continue to grow (excluding M&A)




Gross capex, M€and %- of revenue

Net capex, M€and %- of revenue



Terveystalo Strong operating cash flow, IFRS 16 visible in the operating cash flow and cash flow from investing activities











Q1: The Attendo deal had a significant impact on revenue




Revenue split by customer group, %

Revenue split by customer group, M€




Q1: Stable revenue growth in all payer groups, excluding the Attendo impact

Q1 2019 Revenue split by payer group, excluding Attendo, %



Q1 2019 Revenue split by payer group, excluding Attendo, M€



IFRS 16 impact on reported figures



| | H1/2019 | H1/2019 | H1/2019 | H1/2018 | |
|-------------------------------------|----------|----------------|--------------------------|----------|--|
| EUR mill. | Reported | IFRS 16 impact | Before IFRS 16 impact | Reported | |
| Revenue | 526.4 | - | 526.4 | 386.5 | |
| EBITDA | 85.8 | 19.8 | 66.0 | 62.5 | |
| Adjusted EBITDA | 88.7 | 19.8 | 68.9 | 56.3 | |
| Depreciation | -44.2 | -19.1 | -25.2 | -20.4 | |
| Adjusted EBITA | 58.3 | 0.7 | 57.6 | 45.8 | |
| Financial expenses (net) | -7.3 | -1.8 | -5.5 | -5.1 | |
| Profit/loss before taxes | 34.2 | -1.1 | 35.3 | 37.2 | |
| Taxes | -6.6 | 0.3 | -6.9 | 5.5 | |
| Net profit/loss | 27.6 | -0.8 | 28.4 | 42.6 | |
| Assets | 1,361.3 | 179.9 | 1,181.4 | 933.6 | |
| Financial liabilities | 615.5 | 181.4 | 434.1 | 289.6 | |
| Cash flow from operating activities | 97.7 | 19.8 | 77.9 | 48.6 | |

Key Figures

Terveystalo

| M€ | 4-6/ | 4-6/ | Change, | 1-6/ | 1-6/ | Change, | 2018 |
|--|-------|-------|---------|-------|-------|---------|-------|
| Me | 2019 | 2018 | % | 2019 | 2018 | % | 2018 |
| Revenue | 258.6 | 189.0 | 36.8 | 526.4 | 386.5 | 36.2 | 744.7 |
| Adjusted EBITDA ^{1) 2)} | 40.9 | 25.5 | 60.5 | 88.7 | 56.3 | 57.7 | 108.9 |
| Adjusted EBITDA, % ^{1) 2)} | 15.8 | 13.5 | - | 16.9 | 14.6 | - | 14.6 |
| Adjusted EBITA ^{1) 2)} | 25.9 | 20.2 | 28.2 | 58.3 | 45.8 | 27.3 | 87.7 |
| Adjusted EBITA, % ^{1) 2)} | 10.0 | 10.7 | - | 11.1 | 11.9 | - | 11.8 |
| EBIT ²⁾ | 16.7 | 22.1 | -24.5 | 41.6 | 42.0 | -1.1 | 75.4 |
| Profit for the period ²⁾ | 10.4 | 15.4 | -32.6 | 27.6 | 42.6 | -35.3 | 68.7 |
| Net debt ²⁾ | - | - | - | 572.9 | 218.0 | 162.7 | 413.3 |
| Net debt/Adjusted EBITDA (LTM) ^{1) 2) 3)} | - | - | - | 4.1 | 2.1 | - | 3.8 |
| ROE, % ¹⁾ | - | - | - | 10.5 | 8.8 | - | 14.2 |
| Equity ratio, % ^{1) 2)} | - | - | - | 37.8 | 52.9 | - | 44.1 |
| Gearing)% ^{1) 2)} | - | - | - | 111.4 | 44.2 | - | 80.8 |
| EPS ²⁾ | 0.08 | 0.12 | - | 0.22 | 0.33 | - | 0.54 |
| Operating cash flow ²⁾ | 48.6 | 30.2 | | 97.7 | 48.6 | | 100.6 |
| Personnel (end of period) | | | | 7,165 | 4,531 | 58.1 | 6,018 |
| Private practitioners (end of period) | | | | 5,000 | 4,629 | 8.1 | 4,877 |
| Number of working days | 60 | 61 | -1.6 | 123 | 124 | -0.8 | 251 |
| | 4-6/ | 4-6/ | Muutos, | 1-6/ | 1-6/ | Muutos, | |
| Before IFRS 16 impact (comparable), EUR million | 2019 | 2018 | % | 2019 | 2018 | % | 2018 |
| Adjusted EBITDA 1) | 30.9 | 25.5 | 21.3 | 68.9 | 56.3 | 22.5 | 108.9 |
| Adjusted EBITDA, % ¹⁾ | 11.9 | 13.5 | - | 13.1 | 14.6 | - | 14.6 |
| Adjusted EBITA ¹⁾ | 25.5 | 20.2 | 26.1 | 57.6 | 45.8 | 25.7 | 87.7 |
| Adjusted EBITA, % ¹⁾ | 9.9 | 10.7 | - | 10.9 | 11.9 | - | 11.8 |
| Adjusted net debt | - | - | - | 391.4 | 218.0 | 79.5 | 413.3 |
| Adjusted net debt/adjusted EBITDA) (last) 12 months ^{1) 3)} | - | - | - | 3.2 | 2.1 | - | 3.8 |
| | | | | | | | |

1) Alternative performance measure. Additional information in note 14.

2) Not comparable because of the adoption of IFRS 16.

3) Last 12 months EBITDA includes six-month impact of the Attendo acquisition